News - Cardio-vascular, The Medicines Company


Popular Filters

FDA advisory committee votes against approval of antiplatelet therapy cangrelor

FDA advisory committee votes against approval of antiplatelet therapy cangrelor


The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday…

cangrelorCardio-vascularPharmaceuticalRegulationThe Medicines CompanyUSA

Swedish registry questions superiority of bivalirudin over heparin in patients undergoing PCI for NSTE-ACS


Results from a large observational study reported at EuroPCR 2013 (the official annual meeting of the…

AngiomaxbivalirudinCardio-vascularheparinPharmaceuticalResearchThe Medicines Company

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol


USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

The Medicines Company expands into Russian pharmaceutical market


US drugmaker The Medicines Company (Nasdaq: MDCO) is expanding into Russia, through the start of sales…

AngioxCardio-vascularEuropeMarkets & MarketingPharmaceuticalThe Medicines Company

AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars


Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its…

AstraZenecaCardio-vascularFinancialLicensingManagementPharmaceuticalThe Medicines Company

The Medicines Co settles with APP over Angiomax


The Medicines Company (Nasdaq: MDCO) says that it has settled the law suits filed by company in the US…

AngiomaxAPP PharmaceuticalsCardio-vascularFresenius KabiGenericsLegalNorth AmericaPatentsPharmaceuticalThe Medicines Company

Back to top